[A18-06] Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Last updated 02.05.2018
Commission awarded on 16.01.2018 by the Federal Joint Committee (G-BA).
Immune system and infections
Adults with active relapsing multiple sclerosis (RMS) or with early primary progressive multiple sclerosis (PPMS)
Active RMS: proof of considerable (< 40 years) or minor (≥ 40 years) added benefit; highly active RMS: indication of considerable added benefit. PPMS: indication of lesser benefit than appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-38||Ocrelizumab (multiple sclerosis) - Addendum to Commission A18-06||Commission completed|
Federal Joint Committee (G-BA)
2018-08-02 A G-BA decision was published.